Rita C. Acúrcio

Rita C. Acúrcio

Auto-generated profile, based on publicly available information

Rita C. Acúrcio

University of Lisbon 3 Lisbon

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
CPCarina Peres
Carina Peres
AMAna I. Matos
Ana I. Matos
LMLiane I.F. Moura
Liane I.F. Moura
RARita C. Acúrcio
Rita C. Acúrcio
BCBarbara Carreira
Barbara Carreira
HFHelena Florindo
Helena Florindo

29 August 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
TPTeresa Faria Pais
Teresa Faria Pais
HAHajrabibi Ali
Hajrabibi Ali
JSJoana Moreira da Silva
Joana Moreira da Silva
NDNádia Duarte
Nádia Duarte
RNRita Neres
Rita Neres
CPCarlos Penha-Goncalves
Carlos Penha-Goncalves
Cerebral malaria (CM) is a life-threatening form of Plasmodium falciparum infection caused by brain inflammation. Brain endothelium dysfunction is a hallmark of CM pathology, which is also associated with the activation of the type I interferon (IFN) inflammatory pathway. The molecular triggers and sensors eliciting brain type I IFN cellular responses during CM remain largely unknown. We herein identified the stimulator of interferon response cGAMP interactor 1 (STING1) as the key innate immune sensor that induces Ifnβ1 transcription in the brain of mice infected with Plasmodium berghei ANKA ( Pba ). This STING1/IFNβ-mediated response increases brain CXCL10 governing the extent of brain leukocyte infiltration and blood–brain barrier (BBB) breakdown, and determining CM lethality. The critical role of brain endothelial cells (BECs) in fueling type I IFN–driven brain inflammation was demonstrated in brain endothelial–specific IFNβ-reporter and STING1-deficient Pba -infected mice, which were significantly protected from CM lethality. Moreover, extracellular particles (EPs) released from Pba -infected erythrocytes activated the STING1-dependent type I IFN response in BECs, a response requiring intracellular acidification. Fractionation of the EPs enabled us to identify a defined fraction carrying hemoglobin degradation remnants that activates STING1/IFNβ in the brain endothelium, a process correlated with heme content. Notably, stimulation of STING1-deficient BECs with heme, docking experiments, and in vitro binding assays unveiled that heme is a putative STING1 ligand. This work shows that heme resultant from the parasite heterotrophic activity operates as an alarmin, triggering brain endothelial inflammatory responses via the STING1/IFNβ/CXCL10 axis crucial to CM pathogenesis and lethality.

18 July 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RARita C Acúrcio
Rita C Acúrcio
ASAnna Scomparin
Anna Scomparin
JCJoão Conniot
João Conniot
Jorge A. R. SalvadorJorge A. R. Salvador
Jorge A. R. Salvador
RSRonit Satchi-Fainaro
Ronit Satchi-Fainaro
Rita GuedesRita Guedes
Rita Guedes

5 June 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
João GonçalvesJoão Gonçalves
João Gonçalves
MSM. Santos
M. Santos
RAR. Acurcio
R. Acurcio
III. Iria
I. Iria
Luis Pleno GouveiaLuis Pleno Gouveia
Luis Pleno Gouveia
SDS. Danese
S. Danese

17 July 2014 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
Raquel SoengasRaquel Soengas
Raquel Soengas
RARita C. Acúrcio
Rita C. Acúrcio
Artur M. S. SilvaArtur M. S. Silva
Artur M. S. Silva

29 July 2019 in MedChemComm
Verified
Journal Article
Closed access
PDF file
RARita C. Acúrcio
Rita C. Acúrcio
CLCarlota Leonardo-Sousa
Carlota Leonardo-Sousa
Alfonso T. Garcia-SosaAlfonso T. Garcia-Sosa
Alfonso T. Garcia-Sosa
Jorge A. R. SalvadorJorge A. R. Salvador
Jorge A. R. Salvador
HFHelena Florindo
Helena Florindo
Rita GuedesRita Guedes
Rita Guedes
Programmed cell death protein 1 (PD-1) and PD-ligand 1 (PD-L1) interaction plays an important role in cancer immunotherapy. Several PD-1/PD-L1 inhibitors have been approved with remarkable impact on overall patient survival rates. Inhibitors in clinical practice are presently limited to monoclonal antibodies. However, their severe shortcomings expose the need for a new generation of PD-L1 inhibitors. Understanding the tumor microenvironment, identifying specific biomarkers and X-ray crystalline structures of PD-1/PD-L1 complexes, including molecular and genomic signature studies are essential to determine the success for the development of PD-1/PD-L1 inhibitors into safer and efficient cancer immunotherapeutics. Currently, the development of immune-modulatory small molecules is being explored due to their benefits over recombinant protein approaches. Nevertheless, their development is hampered in part due to lack of structural information. The current study builds on PD-L1 small-molecule inhibitor structural information and provides insights into the design of new inhibitors. To this end, a comprehensive analysis of crystallographic structures and benchmarking studies were performed, showing the specific structure model and software best suited to study PD-L1. The use of in silico methodologies can give a deeper insight to guide the design of novel PD-L1 small-molecule inhibitors.